u/saskia_lokken

redact member ids and group numbers from every screenshot

Small correction: the trial was 20 weeks, not 17. Does not change your point but people will quote it.

incretin physiology is mechanism, the mechanism layer

Respectfully this is a sample of one presented as a finding.

IANAD and neither is anyone upvoting this

the 11-day half-life means week 11 is still ramp-up pharmacokinetically

resubmission after denial requires new documentation

Strongly agree. Step therapy is predictable if you have the criteria.

sulphur burps are disgusting but not dangerous, 11 weeks and they stopped

Strongly agree. Describe your dose, your week number, and your titration speed or nobody can help.

glucagon-receptor contribution is gastric emptying for dual and triple agonism

amylin is not GLP-1, posts conflating them get corrected

external review is the appeal after insurance says no

Slight fix: the number was 99.2, not 99.1. Decimal point, but a fairly consequential one.

Which plan type? appeal is different.

External review overturned the denial. Took 5 weeks but the process exists.

Half-life is about 168 hours, so steady state lands around week 2–5.

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

Not convinced. The evidence does not support that reading.

step therapy documentation is the weapon, use it